Welcome to our dedicated page for LB Pharmaceuticals SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LB Pharmaceuticals Inc (LBRX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission, alongside AI-assisted summaries to help interpret the information. As a clinical-stage biopharmaceutical company focused on schizophrenia, bipolar depression, and other neuropsychiatric diseases, LB Pharmaceuticals uses SEC filings to report on its financial condition, clinical development plans, corporate governance, and material agreements.
Core documents for LBRX include its registration statement on Form S-1/A, which describes the company’s business, risk factors, and the role of its lead product candidate, LB-102. This filing outlines LB-102’s status as a Phase 3–ready oral, small-molecule drug and a methylated derivative of amisulpride, and explains the company’s focus on neuropsychiatric indications such as acute schizophrenia and bipolar depression. Periodic reports and earnings-related Form 8-K filings provide condensed balance sheets, statements of operations, and narrative updates on research and development and general and administrative expenses.
Other current reports on Form 8-K document material corporate events, including lease amendments for additional office space, appointments of senior executives, and press releases announcing quarterly financial results. These filings also confirm that LB Pharmaceuticals’ common stock is listed on The Nasdaq Stock Market LLC under the ticker LBRX and that the company is incorporated in Delaware.
On Stock Titan, users can review these filings in chronological order and use AI-powered summaries to quickly understand key points from lengthy documents, such as the implications of clinical trial disclosures, changes in operating expenses, or the significance of material agreements. Access to insider transaction reports on Form 4, annual reports on Form 10-K, and quarterly reports on Form 10-Q, when filed, can further support analysis of LBRX’s progress as a clinical-stage biopharmaceutical issuer.
Ran Nussbaum, a director associated with Pontifax entities, reported acquisitions of LB Pharmaceuticals (LBRX) securities on 09/12/2025. The filing shows an automatic conversion of Series C redeemable convertible preferred stock into common stock and a purchase of common shares. Specifically, 10,000,000 shares of Series C preferred were converted immediately prior to the companys IPO closing, and 1,000,000 common shares were acquired at $15.00 per share. After these transactions, the reporting person (through Pontifax-related entities) beneficially owned 1,411,681 common shares, held indirectly. The filing identifies Pontifax (Israel) VI LP and Pontifax (Cayman) VI LP as holders of the underlying securities and notes shared voting and investment power through Pontifax management.
Vida Ventures reporting persons recorded multiple transactions in LB Pharmaceuticals, Inc. (LBRX) on 09/12/2025. Series C preferred shares held by Vida entities converted into common stock immediately prior to the issuer's IPO under a conversion mechanism tied to the IPO price. Vida Ventures III, L.P. reported 547,648 common shares beneficially owned following conversion; Vida Ventures III-A, L.P. reported 1,262 common shares; Vida Ventures Management Co. LLC reported 1,434 common shares.
Additionally, purchases at $15.00 per share were reported: Vida Ventures III, L.P. acquired 332,566 common shares and Vida Ventures III-A, L.P. acquired 767 common shares, bringing Vida Ventures III total to 880,214 and Vida Ventures III-A to 2,029 beneficially owned shares as shown on the form.
LB Pharmaceuticals (LBRX) reports Phase 2 results for LB-102 showing statistically significant improvement on the PANSS overall score at 50 mg, 75 mg and 100 mg versus placebo and a favorable tolerability profile with mostly transient, mild-to-moderate adverse events. The company observed a statistically significant impact on negative symptoms at the 50 mg dose and exploratory post-hoc analyses supported cognitive benefits on CogState testing. Based on end-of-Phase 2 feedback, management believes the Phase 2 trial may serve as one of two pivotal trials and plans a single six-week, three-arm, inpatient, double-blind Phase 3 trial (50 mg, 100 mg, placebo) to start in Q1 2026 with ~400 U.S. patients across ~25 sites, primary endpoint change in PANSS at Day 42, topline data expected H2 2027 and an FDA meeting planned Q1 2028 if results are positive.
The company is also initiating LB-102 development in bipolar depression with a Phase 2 trial planned in Q1 2026 and topline data expected Q1 2028. Financially, recent periods show operating losses (e.g., pro forma net loss figures presented) and the company discloses pro forma as adjusted cash and marketable securities balances consistent with its offering plan to advance LB-102 into Phase 3 and other NDA-enabling studies.